Ignite Creation Date:
2024-05-05 @ 5:24 PM
Last Modification Date:
2024-10-26 @ 9:31 AM
Study NCT ID:
NCT00446082
Status:
COMPLETED
Last Update Posted:
2020-12-21
First Post:
2007-03-09
Brief Title:
Study of Pasireotide Long Acting Release LAR Injection in Patients With Acromegaly and Patients With Carcinoid Disease
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis
Study Overview
Official Title:
A Phase I Multicenter Open-label Randomized Study Assessing the Pharmacokinetics Safety and Tolerability of Monthly Doses of Pasireotide im LAR Injection in Patients With Acromegaly and Patients With Carcinoid Disease
Status:
COMPLETED
Status Verified Date:
2016-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will assess the pharmacokinetic profile and the safetytolerability profile of single and monthly doses of pasireotide LAR intramuscular im injection in patients with acromegaly and patients with carcinoid disease
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2005-003348-75 | EUDRACT_NUMBER | None | None |